MDxHealth SA (NASDAQ:MDXH) Short Interest Up 171.7% in April

MDxHealth SA (NASDAQ:MDXH) was the target of a significant increase in short interest during the month of April. As of April 30th, there was short interest totaling 52,208 shares, an increase of 171.7% from the April 15th total of 19,213 shares. Based on an average trading volume of 128,113 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.1% of the company’s stock are sold short.

MDxHealth Stock Down 9.3%

NASDAQ:MDXH traded down $0.09 during mid-day trading on Friday, reaching $0.89. The stock had a trading volume of 3,275,116 shares, compared to its average volume of 797,714. MDxHealth has a 1-year low of $0.68 and a 1-year high of $5.33. The stock’s 50 day simple moving average is $2.42 and its two-hundred day simple moving average is $3.23.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The firm had revenue of $23.90 million during the quarter, compared to analyst estimates of $30.89 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 29.90%. Sell-side analysts predict that MDxHealth will post -0.41 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on MDXH. Wall Street Zen lowered MDxHealth from a “hold” rating to a “strong sell” rating in a research report on Saturday. BTIG Research dropped their target price on MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday. TD Cowen reaffirmed a “buy” rating and set a $1.50 target price (down from $7.00) on shares of MDxHealth in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a research report on Friday, March 27th. Finally, Lake Street Capital dropped their target price on MDxHealth from $9.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $4.63.

Hedge Funds Weigh In On MDxHealth

A number of hedge funds and other institutional investors have recently bought and sold shares of MDXH. GSA Capital Partners LLP acquired a new position in MDxHealth in the third quarter valued at approximately $48,000. Jefferies Financial Group Inc. acquired a new position in MDxHealth in the third quarter valued at approximately $53,000. Russell Investments Group Ltd. acquired a new position in MDxHealth in the third quarter valued at approximately $461,000. Kennedy Capital Management LLC acquired a new position in MDxHealth in the third quarter valued at approximately $1,826,000. Finally, FreeGulliver LLC boosted its stake in MDxHealth by 104.7% in the third quarter. FreeGulliver LLC now owns 252,894 shares of the company’s stock valued at $1,176,000 after acquiring an additional 129,348 shares during the period.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.